Tag: solid tumors

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

BOSTON, July 4, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart...

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma...

Adverse events were generally low-grade, transient, and readily manageable

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsSolid tumors

IGM FINANCIAL INC. ANNOUNCES JUNE 2025 ASSETS UNDER MANAGEMENT & ADVISEMENT AND NET FLOWS

The Dermatology Group of Arkansas Welcomes Double Board-Certified Dermatologist to Practice

Nova Klúbburinn hf.: Flöggun – Íslandsbanki hf.

Tag: solid tumors

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us